Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRX NASDAQ:CBAY NYSE:CTST NASDAQ:CYAD NASDAQ:HROW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsCBAYCymaBay Therapeutics$32.48$32.44$7.26▼$32.50$3.73B0.324.11 million shs73 shsCTSTCannTrustC$0.64C$0.64C$0.38▼C$8.17C$90.27MN/AN/AN/ACYADCelyad$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsHROWHarrow$34.23-3.9%$29.03$20.85▼$59.23$1.26B0.41497,746 shs318,263 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CBAYCymaBay Therapeutics0.00%0.00%0.00%0.00%0.00%CTSTCannTrust0.00%0.00%0.00%0.00%0.00%CYADCelyad0.00%0.00%0.00%0.00%0.00%HROWHarrow+1.98%+13.58%+17.52%+49.73%+50.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACTSTCannTrustN/AN/AN/AN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/AN/AN/AN/AHROWHarrow2.2214 of 5 stars3.51.00.00.02.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRXAcelRx Pharmaceuticals 0.00N/AN/AN/ACBAYCymaBay Therapeutics 0.00N/AN/AN/ACTSTCannTrust 0.00N/AN/AN/ACYADCelyad 0.00N/AN/AN/AHROWHarrow 3.00Buy$63.8379.21% UpsideCurrent Analyst Ratings BreakdownLatest ACRX, CYAD, CBAY, HROW, and CTST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$76.006/12/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.006/10/2025HROWHarrowWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/12/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$57.00 ➝ $60.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRXAcelRx Pharmaceuticals$1.77M0.00N/AN/A$2.65 per share0.00CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59CTSTCannTrustC$35.22M2.56N/AN/AN/A∞CYADCelyad$200K79.56N/AN/A$0.02 per share30.00HROWHarrow$199.61M6.55$0.14 per share255.45$1.95 per share18.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRXAcelRx Pharmaceuticals$47.76M-$2.23N/AN/AN/AN/A-81.54%-46.02%N/ACBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/ACTSTCannTrust-C$10.46MN/A0.00∞N/AN/AN/AN/AN/ACYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/AHROWHarrow-$17.48M-$0.56N/A89.05N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)Latest ACRX, CYAD, CBAY, HROW, and CTST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025HROWHarrow$0.01N/AN/AN/A$64.23 millionN/A5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/ACTSTCannTrustN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRXAcelRx PharmaceuticalsN/A4.044.04CBAYCymaBay TherapeuticsN/A10.9610.96CTSTCannTrustN/AN/AN/ACYADCelyad1.492.292.14HROWHarrow2.010.910.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRXAcelRx Pharmaceuticals19.79%CBAYCymaBay Therapeutics95.03%CTSTCannTrust0.03%CYADCelyadN/AHROWHarrow72.76%Insider OwnershipCompanyInsider OwnershipACRXAcelRx Pharmaceuticals3.00%CBAYCymaBay Therapeutics7.00%CTSTCannTrustN/ACYADCelyad0.94%HROWHarrow13.67%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRXAcelRx Pharmaceuticals1916.95 million16.44 millionOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableCTSTCannTrust576141.49 millionN/AOptionableCYADCelyad9526.52 million26.28 millionNot OptionableHROWHarrow18036.69 million31.67 millionOptionableACRX, CYAD, CBAY, HROW, and CTST HeadlinesRecent News About These CompaniesFY2026 Earnings Estimate for Harrow Issued By William BlairJuly 15 at 8:23 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROWJuly 14 at 1:26 PM | bakersfield.comBHarrow (NASDAQ:HROW) Shares Up 5.7% - What's Next?July 14 at 12:30 PM | marketbeat.comHarrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?July 14 at 11:06 AM | zacks.comRice Hall James & Associates LLC Has $7.88 Million Holdings in Harrow, Inc. (NASDAQ:HROW)July 14 at 6:36 AM | marketbeat.comCantor Fitzgerald Initiates Coverage on Harrow (NASDAQ:HROW)July 14 at 2:47 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWJuly 12 at 10:00 AM | prnewswire.comCantor Fitzgerald Initiates Coverage of Harrow (HROW) with Overweight RecommendationJuly 11, 2025 | msn.comHarrow jumps as Cantor initiates with Bullish view on conservative outlookJuly 11, 2025 | msn.comHarrow (NASDAQ:HROW) Shares Gap Up - What's Next?July 11, 2025 | marketbeat.comHarrow (NASDAQ:HROW) Coverage Initiated at Cantor FitzgeraldJuly 11, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. ...July 10, 2025 | gurufocus.comHarrow, Inc. (NASDAQ:HROW) Receives $61.40 Average PT from BrokeragesJuly 10, 2025 | americanbankingnews.comHarrow: Immense Upside PotentialJuly 9, 2025 | seekingalpha.comHROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - MorningstarJuly 7, 2025 | morningstar.comMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWJuly 7, 2025 | prnewswire.comHarrow, Inc. (NASDAQ:HROW) Given Average Recommendation of "Buy" by BrokeragesJuly 7, 2025 | marketbeat.comHROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law FirmJuly 6, 2025 | gurufocus.comHROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law FirmJuly 6, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROWJuly 6, 2025 | globenewswire.comWilliam Blair Initiates Coverage of Harrow (HROW) With an Outperform RatingJuly 6, 2025 | msn.comMedia Sentiment Over TimeACRX, CYAD, CBAY, HROW, and CTST Company DescriptionsAcelRx Pharmaceuticals NASDAQ:ACRXAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.CymaBay Therapeutics NASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.CannTrust NYSE:CTSTCannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.Celyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Harrow NASDAQ:HROW$34.23 -1.39 (-3.90%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Analysts Set $600 Target Ahead of Microsoft Earnings NVDA Greenlight: China H20 Sales Spark 50% Rally Potential New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? Will Dollar Tree Break Out After a New $2.5 Billion Buyback? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
